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Background: Transcranial direct current stimulation (tDCS) is used for various chronic
pain conditions, but experience with tDCS for acute postoperative pain is limited. This
study investigated the effect of tDCS vs. sham stimulation on postoperative morphine
consumption and pain intensity after thoracotomy.
Methods: This is a single-center, prospective, randomized, double-blind, sham-
controlled trial in lung cancer patients undergoing thoracotomy under general
anesthesia. All patients received patient-controlled (PCA) intravenous morphine and
intercostal nerve blocks at the end of surgery. The intervention group (a-tDCS, n = 31)
received anodal tDCS over the left primary motor cortex (C3-Fp2) for 20 min at 1.2 mA, on
five consecutive days; the control group (n = 31) received sham stimulation. Morphine
consumption, number of analgesia demands, and pain intensity at rest, with movement
and with cough were recorded at the following intervals: immediately before (T1),
immediately after intervention (T2), then every hour for 4 h (Т3–Т6), then every 6 h
(Т7–Т31) for 5 days. We recorded outcomes on postoperative days 1 and 5 and
conducted a phone interview inquiring about chronic pain 1 year later (NCT03005548).
Results: A total of 62 patients enrolled, but tDCS was prematurely stopped in six patients.
Fifty-five patients (27 a-tDCS, 28 sham) had three or more tDCS applications and were
included in the analysis. Cumulative morphine dose in the first 120 h after surgery was
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significantly lower in the tDCS [77.00 (54.00–123.00) mg] compared to sham group
[112.00 (79.97–173.35) mg, p = 0.043, Cohen’s d = 0.42]. On postoperative day 5,
maximum visual analog scale (VAS) pain score with cough was significantly lower in the
tDCS group [29.00 (20.00–39.00) vs. 44.50 (30.00–61.75) mm, p = 0.018], and pain
interference with cough was 80% lower [10.00 (0.00–30.00) vs. 50.00 (0.00–70.00), p =
0.013]. One year after surgery, there was no significant difference between groups with
regard to chronic pain and analgesic use.
Conclusion: In lung cancer patients undergoing thoracotomy, three to five tDCS
sessions significantly reduced cumulative postoperative morphine use, maximum VAS
pain scores with cough, and pain interference with cough on postoperative day 5, but
there was no obvious long-term benefit from tDCS.
Keywords: transcranial direct current stimulation, randomized double-blind study, prospective study, pain
management, acute pain, analgesia
INTRODUCTION
Thoracotomy is a painful incision that involves multiple muscle
layers, rib resection and pain is exacerbated by ongoing
continuous movement due to breathing (Gerner, 2008). In
addition, published data suggest that acute post-thoracotomy
pain can influence the appearance and intensity of chronic post-
thoracotomy pain (Katz et al., 1996; Bayman et al., 2017; Kampe
et al., 2017).
Thoracic epidural analgesia is considered as gold standard for
pain after thoracotomy, whereas systemic analgesia is used in
patients not eligible for epidural analgesia (Gottschalk et al.,
2006; Kampe et al., 2013; Kampe et al., 2014; Maxwell and
Nicoara, 2014). Because multimodal analgesia regimens include
pharmacological agents with potential for significant adverse
events, there is an opportunity in post-thoracotomy pain
management for development of new, improved techniques
with fewer adverse events.
Transcranial direct current stimulation (tDCS) is a noninvasive
cortical stimulation technique with neuromodulatory effects,
altering cortical excitability through subthreshold modulation of
neuronal resting membrane potentials by constant weak electrical
current (Nitsche et al., 2003a; Nitsche et al., 2008; Stagg and
Nitsche, 2011).
The proposed mechanism of pain alleviation by tDCS is based
on modulation of cortical excitability in locations that can be
considered as entry points for the wider areas of neuronal
networks, the so-called “pain matrix” (Ayache et al., 2016).
However, in addition to this mechanism, recent evidence
indicates an interaction of tDCS with a number of
neurotransmitter systems (serotonin, dopamine, GABA,
acetylcholine) (Knotkova et al., 2013), as well as changes in
serum brain-derived neurotrophic factor (BDNF) levels, which
also take part in the processing of painful stimuli (Stefani et al.,
2012). Furthermore, in addition to local effects in the area of
stimulation, significant changes in remote connected areas
related to processing of motor, cognitive, or pain information
have also been demonstrated (Stagg et al., 2013).
Published data suggest that tDCS, when used as part of
multimodal postoperative analgesia can result in reduced
postoperative opioid use and reduced pain in patients
undergoing endoscopic retrograde cholangiopancreatography
(ERCP) (Borckardt et al., 2011), total knee arthroplasty
(Borckardt et al., 2013; Borckardt et al., 2017; Khedr et al.,
2017b), and hallux valgus surgery (Ribeiro et al., 2017), while
results for patients who underwent lumbar spine surgery are
equivocal (Dubois et al., 2013; Glaser et al., 2016).
Advantages of tDCS use for postoperative analgesia include
simplicity of use, patient comfort, absence of a magnetic field,
and low cost, and therefore tDCS is a promising option as non-
pharmacological addition to a multimodal postoperative
analgesia regimen (Borckardt et al., 2009; Bikson et al., 2016;
Antal et al., 2017). Furthermore, tDCS with standard parameters
seems to be safe, and the combination of tDCS with pain
medications has not been associated with significant safety
issues (Antal et al., 2017).
The primary objective of this single-center, prospective,
randomized, double-blind clinical trial is to evaluate the effect
of anodal tDCS combined with patient-controlled analgesia
(PCA) morphine, on intravenous (IV) morphine consumption
for analgesia after thoracotomy. The intervention group received
treatment with anodal tDCS, whereas the control group received
sham stimulation. We hypothesized that tDCS will result in
reduced postoperative morphine use (primary outcome) and
lower postoperative pain intensity at rest, with movement and
with cough (secondary outcome) in patients receiving IV
morphine PCA for analgesia after thoracotomy.
METHODS
Study Design and Patient Selection
This prospective, randomized, double-blinded sham/controlled
study was carried out in the Department of Cardiothoracic
Surgery and the Department of Anesthesia and Intensive Care
at the Military Medical Academy in Belgrade (Serbia) in the
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period from June 15, 2016 to March 27, 2018. The study was
approved by the Institution Ethics Committee and was registered
in Clinical Trials: https://clinicaltrias.gov (registration number
NCT03005548). All eligible patients received detailed
information about the study protocol and goals and gave
written consent before enrolling in the study.
Inclusion criteria were patient willingness to participate,
ability to understand the protocol and provide written
informed consent, age 18–80, scheduled thoracotomy for
confirmed primary malignant lung disease, and planned
tracheal extubation in the operating room immediately after
surgery. Exclusion criteria were pregnancy, treatment for
neurological or psychiatric diseases, any chronic pain
condition, history of alcohol or drug abuse, chemotherapy,
history of previous thoracic or cardiac surgery, allergy to
medications used in the study, presence of pacemaker,
automatic implantable cardioverter/defibrillator or any other
implanted device in the head, spinal cord, or peripheral nerves,
and confirmed brain lesion, including tumor or metastasis
(Woods et al., 2016). The flowchart of the study is presented in
Figure 1.
Patients in both groups received intraoperative IV morphine
followed by postoperative IV morphine PCA (bolus 1 mg,
lockout time 10 min) using the CADDLegacy PCA Pump
(Deltec, Inc.). Patients assigned to the active treatment group
(a-tDCS, n = 31), received tDCS (20 min of 1.2 mA anodal tDCS
over the left primary motor cortex for 5 days), whereas patients
assigned to the sham control group (sham-tDCS, n = 31)
received sham tDCS stimulations over the left primary motor
cortex for 5 days.
Sample Size Calculation
Sample size calculation was conducted using the freely available
from the University of Dusseldorf, Germany, G*Power statistical
program v. 3.1.9.2 (Faul et al., 2007) and was based on the following
assumptions: two tailed t-test, beta error = 0.2 (power of 80%),
FIGURE 1 | Study flowchart. VATS, video-assisted thoracoscopic surgery; tDCS, transcranial direct current stimulation.
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alpha = 0.05, mean morphine consumption 39 mg in one group vs.
62 mg in the other group with SD = 30, based on previously
published data (Borckardt et al., 2008). Based on these assumptions,
the required sample size would be 28 patients per group. Therefore,
because we assumed 10% overall attrition rate, we decided to
increase the sample size by 10% to 31 patients per group.
Participating patients were instructed to continue the study
for 5 days. Criteria for early discontinuation of the study
included the absence of any pain, patient request (for any
reason), adverse analgesic medication or tDCS effects and any
complications requiring prolonged postoperative intubation,
mechanical ventilation, or additional surgical interventions.
Randomization and Blinding
In order to preserve blinding, only one independent physician
(TVI) was in charge of the randomization procedure and
adjusted tDCS in either anodal or placebo mode but had no
contact with the patient and was not involved in any stage of
collecting or processing data. All other investigators were blinded
to group assignment. The tDCS stimulation session was
performed by an investigator who had no knowledge of other
aspects of patient data. After the first tDCS session, all patients
were asked if they thought they were receiving active or sham
stimulation. Analysis of their response did not show any
significant findings, therefore we concluded that the blinding
procedure was probably successful.
Group allocation was masked as group 1 or 2 for statistical
analysis. Group allocation to the active tDCS (intervention) group
or the sham (control) group was revealed after final data analysis.
A computer-generated permuted block randomization
method (1:1) was used to allocate patients to the active or
sham tDCS groups based on order of inclusion in the study, in
order to ensure concealment.
Intervention
tDCS was transmitted through two circular Ag/AgCl electrodes
(1 cm radius) with conductive gel fixed by the neoprene head cap
and was delivered by a battery-driven, wireless Starstim tDCS
neurostimulator (Neuroelectrics, Barcelona, Spain). The anode
was placed over the left primary motor cortex, Brodmann area 4
(C3 position of the International 10-20 electroencephalogram
electrode system), and the return electrode was placed over the
contralateral supraorbital region (Fp2). The anodal tDCS group
received stimulation for 20 min at 1.2 mA (current density 0.38
mA/cm2; charge density 0.127 mAh/cm2) per session. In sham
stimulations, current was applied over the same electrode
montage for 60 s with a ramp time of 10 s and then gradually
turned off at the start of the 20-min period. At the end of the
period, the current was ramped up slowly and then turned off
more quickly (Nitsche et al., 2003b).
Anesthesia, Surgery, and Perioperative
and Postoperative Pain Management
Protocol
Patients were screened for possible inclusion in the study the day
before surgery. Then, an investigator approached each eligible
patient and provided information about the study, perioperative
course, the expected level of acute postoperative pain, and
incidence of chronic pain after thoracotomy. After signing a
written consent, patients were instructed on the use of the visual
analog (VAS) for assessment of pain and on the use of the PCA
pump and received additional information about the tDCS
procedure. In addition, on the morning of surgery patients
were once again checked to ensure that they understand the
pain assessment score and had their VAS for anxiety and
depression assessed. After arrival in the operating room,
standard monitoring was placed, IV access was obtained, and
midazolam 2 mg was given as premedication. General anesthesia
was induced using target-controlled infusion (TCI) of
remifentanil (1–5 ng ml−1) and propofol (5 µg ml−1), while cis-
atracurium (0.2 mg kg−1) was given for muscle relaxation. After
induction, placement of double lumen endotracheal tube and
confirmation of appropriate tube position with bronchoscopy,
anesthesia was maintained with TCI of remifentanil (1–5 ng
ml−1) and propofol (5 µg ml−1), while cis-atracurium (0.03 mg
kg−1) was given as needed to maintain neuromuscular blockade.
Entropy levels (Datex-Ohmeda S/5™ Anesthesia Monitor, GE
Healthcare Finland Oy, Helsinki, Finland) were maintained in
the 40–60 range throughout the procedure and FiO2 was set at
80% in order to keep SaO2 > 92%.
Thoracotomy was performed using a conventional
anterolateral thoracotomy approach (Ferguson, 2007). The
skin incision was 15 to 20 cm long, parallel to the ribs at the
lateral part of the fifth intercostal space. The fifth intercostal
space was crossed by subperiosteal rib resection along the
superior border of the sixth rib. Rib spreader was used for two
ribs retraction, with the superior part of the spreader moving
apart the full content of the intercostal space (including the fifth
intercostal nerve) against the inferior border of the fifth rib. The
procedure was lobectomy or pneumonectomy depending on
intraoperative findings.
During surgery, after resection of the lobe or lung was
completed, we applied positive pressure to the bronchial stump
and lobe in order to confirm the absence of significant
postoperative air leak (“air leak test”) (Fell SC and Feins,
2018). After the “air leak test” morphine 2 mg was given as a
bolus, morphine infusion was started at 0.01–0.05 mg/kg/h and
paracetamol 1000 mg was infused over 30 min. At the beginning
of chest closure, the surgeon performed ipsilateral intercostal
blocks under direct vision at T4 to T7 levels using
levobupivacaine 0.5%, 2 ml per level. At the end of surgery,
intercostal drains were placed, and the intercostal space was
closed by peri-costal sutures. After the end of surgery patients
were extubated and transferred to the Post-Anesthesia Care Unit.
Postoperatively, as soon as VAS at rest was below 30 mm,
tDCS was started and each patient was switched to morphine IV-
PCA (bolus 1 mg, lockout time 10 min) with a dedicated PCA
pump (CADDLegacy PCA Pump, Deltec, Inc., Ashford, Kent,
UK). For patient convenience PCA morphine bolus was
increased from 1 to 2 mg based on the individual increased
number of attempted requests recorded with pump. Patients
received IV morphine PCA for 5 days, but PCA was continued
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beyond postoperative day 5 if needed, but could also be
discontinued earlier if no longer needed or at patient request.
At the ward, all patients were monitored by pulse oximetry. If
analgesia was inadequate (VAS score in rest ≥30 mm), the IV line
was checked, additional morphine 1–2 mg was given as bolus,
and analgesia was supplemented with IV diclofenac 75 mg twice
a day and a single 1000 mg dose of IV paracetamol. After
discontinuation of the IV PCA, patients received IV
paracetamol 1000 mg every 6 h. After hospital discharge,
patients received a prescription for oral nonsteroidal analgesics
or paracetamol but not for any opioids. For the purposes of this
study, data were collected during the first five postoperative days.
Outcomes and Assessments
The primary outcome of this study was the amount of morphine
used for analgesia after thoracotomy in a group of patients
receiving tDCS in comparison with the amount of morphine
used for analgesia in patients receiving sham stimulation for up
to 5 days.
Secondary outcomes were pain scores measured using VAS
(from 0 no pain to 100 mm the worst possible pain) at rest,
during movement, and during cough in patients receiving tDCS
and IV morphine PCA, compared to patients receiving sham
stimulation and IV morphine PCA.
After surgery, the first tDCS session was applied when the
VAS pain score at rest fell below 30 mm. Morphine
consumption, the number of analgesia demands, and pain
intensity at rest, with movement and with cough were
recorded at predetermined time intervals as follows:
immediately before the intervention (T1), immediately after
the intervention (T2), then regularly every 1 h for 4 h
(Т3–Т6), and then every 6 h (Т7–Т31) for 5 days (Figure 2).
A researcher blinded to group assignments evaluated all
patients in the morning on postoperative day 1 and
postoperative day 5 using the patient-related outcomes (PRO)
survey (Rothaug et al., 2013). The PRO survey consists of
questions including the intensity of “the worst possible pain”
(graded from 0 to 100); the percentage of time with severe pain
(graded from 0 to 100%); pain interference with activity, cough,
sleep, and mood (graded from 0 to 100); and patient satisfaction
(0 to 100). The PRO survey was completed by the patients
themselves; the researcher was only responsible for ensuring that
all questions were answered. Baseline pain, anxiety, and
depression were assessed on the morning of surgery and on
the day of discharge from the hospital. Maximum VAS pain
scores (i.e., the highest pain score number reported by each
patient in each time frame) at rest, with movement and with
cough were recorded. Demographic data and comorbidities were
also recorded.
Baseline anxiety level was assessed with VAS for anxiety
(Facco et al., 2013), whereas depressive symptoms were
assessed with the Beck Depression Inventory (Beck et al.,
1996). In addition, we recorded postoperative complications
(surgical complications, allergy, pruritus, nausea, vomiting,
hypotension, respiratory depression, delirium, weakness) and
tDCS complications (headache, tiredness, nausea, tingling,
itching sensations under the electrodes) (Stagg and Nitsche,
2011; Woods et al., 2016).
FIGURE 2 | Study design.
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Management of the chest tube was at the discretion of the
surgeon. Based on the publication by Bayman et al. (2017) a
drain was recorded as “present” if it was present at 7:00 am
during morning rounds. Respiratory complications were defined
based on a study by Canet et al. (2010) and extrapulmonary
complications were recorded based on the definitions of the
PROVIHLO trial (Hemmes et al., 2014).
During hospitalization, after discontinuation of the
intervention we recorded opioid analgesia requests besides
regular paracetamol therapy and the amount of morphine
used. If patients agreed to be contacted, a phone interview was
conducted 1 year after surgery. The interview contained
questions about presence of chronic pain after surgery; if pain
was present, additional questions included time when pain
appeared, medications used for pain treatment, and the
influence of pain on daily activity. Because of concern about
possible adverse effects of tDCS, we prepared a structured
questionnaire in accordance with questionnaire surveys for
tDCS adverse effects (Brunoni et al., 2011), and administered
the questionnaire to all patients after each individual tDCS or
sham session.
Statistical Analysis
In total, 55 patients who received three or more tDCS stimulation
sessions were included in data analysis (Figure 1). Data were
analyzed “per protocol” based on tDCS cumulative effect.
Categorical variables [sex, American Society of Anesthesiologists
Physical Status (ASA) score, smoking, comorbidities, surgery type,
postoperative complications, reasons for tDCS termination,
number of tDCS sessions, number of patients using nonopioid
drugs and pharmacological treatment for chronic pain, and
number of patients with chronic pain] were presented as
frequency and were analyzed using the chi-square test. All
continuous variables [age, body mass index (BMI), surgery
duration, use of remifentanil, propofol and pre tDCS morphine
loading, cumulative morphine dose, VAS, hospitalization duration,
drain, anxiety level, mood, and Beck depression scale score] are
presented as mean ( ± SD) for normally distributed data or median
[interquartile range (IQR): 25–75 percentile] for non-normally
distributed data. The Shapiro–Wilk test was used to test the
normality of data distribution. For intergroup (active vs. sham)
comparisons, the independent t-test was used for parametric
variables (age, BMI, surgery duration, use of remifentanil,
propofol, and pre-tDCS morphine loading), and the Mann–
Whitney U test for non-parametric variables (cumulative
morphine dose, VAS, hospitalization duration, drain, anxiety
level, mood, and Beck depression scale score). The relationship
between variables was evaluated using the Pearson’s coefficient
correlation. Cohen’s d for the mean difference also was performed
for a continuous variable of interest (cumulative morphine dose).
Statistical analysis was conducted using IBM SPSS Statistics,
version 19.0 (SPSS, Chicago, IL, USA) and statistical significance
was defined as p < 0.05 for all comparisons. Missing values were
less than 5%.
The period between two consecutive stimulations was used as
a time frame for data analysis, starting with the time frame
between the first and the second session, the second and the
third, and so on, and therefore there were five time frames: time
after the first session, after the 2nd tDCS, after the 3rd tDCS, after
the 4th tDCS, and after the 5th tDCS session. Morphine dose was
calculated as cumulative dose before every preceding stimulation,
i.e., the dose of morphine between two consecutive stimulations,
including the period 24 h after the last tDCS stimulation. VAS
pain scores were recorded in three different conditions: at rest,
with movement, and with cough at regular time intervals
between consecutive tDCS sessions. The highest VAS score
among these measurements for the individual patient served as
representative for that time frame. Then, we calculated and
presented a median (IQR) of maximum VAS pain scores of all
patients in the group for a particular time frame. The same
principle was applied separately for pain in different conditions.
RESULTS
Overall 62 patients enrolled in the study. One patient was
excluded because he required emergency re-operation. tDCS
was prematurely stopped in six patients due to surgical
complications (n = 2), absence of pain (n = 2), or per patient
request without a specific reason (n = 2). Patients were included
in the analysis only if they received three or more tDCS
applications, and data were analyzed “per protocol” (27 in the
tDCS and 28 in the sham group, 55 in total, as shown in
Figure 1).
Baseline demographic data (Table 1), comorbidities (p =
0.525), intraoperative data (Table 2), and surgery type (p =
0.383) (Table 2), were not significantly different between groups.
Maximum VAS pain scores at rest before intervention were not
significantly different between the tDCS and the sham group
[20.00 (10.00–29.00) vs. 29.00 (22.00–29.75), p = 0.102].
Cumulative morphine dose administered during the first 120
h after surgery was lower by 31.25% (Cohen’s d = 0.42) in the
tDCS group [77.00 (54.00–123.00) vs. 112.00 (79.97–173.35) mg,
p = 0.043], and the difference was statistically significant
(Figure 3). The number of analgesia requests delivered by
PCA pump did not differ significantly between groups.
Additional analysis comparing cumulative morphine use in
men and women in both the tDCS and the sham groups did
not show any significant differences between tDCS vs. sham in
men or in women. However, cumulative morphine use was






Age (years) 61.44 (7.98) 61.89 (5.79) 0.812a
BMI (kg m-2) 26.01 (4.34) 25.81 (4.89) 0.873a
Sex (female/male) 11/16 5/23 0.116b
ASA (2/3) 4/23 3/25 0.959b
Smoking at present 12 (44.4%) 15 (53.6%) 0.248b
Data are presented as mean (SD) or number (percentage). Data analysis did not show any
significant differences between the active vs. sham group.
BMI, body mass index; ASA, American Society of Anesthesiologists Physical Status.
aIndependent t-test.
bChi-square test.
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significantly higher in men, compared to women, in both the
tDCS and the sham group at all time points (Table 3).
On postoperative day 5, maximum VAS pain score with
cough was lower by 34.83% in the tDCS group [29.00 (20.00–
39.00)] vs. sham stimulation [44.50 (30.00–61.75)], p = 0.018;
this difference was confirmed by PROs, where interference of
pain with cough was 80.00% lower [10.00 (0.00-30.00) vs. 50.00
(0.00-70.00), p=0.013] (Figure 4C). There was no significant
difference in maximum VAS pain scores during rest and
movement, between the tDCS and the sham group
(Figures 4A, B). Also, no difference in maximum VAS pain
scores was found in men compared to women in both the tDCS
and the sham group.
We did not record any complications from tDCS, except for
“itching” and “tingling” in the control group. Postoperative
complications included respiratory complications, arrhythmias,
surgical complications, and infections but there was no
significant difference between groups (p = 0.522).
There was no significant difference between groups regarding
anxiety, mood, and presence of depression (Table 4). While
interference of pain with cough was significantly lower in the
active tDCS group, we did not identify any other differences
existed between groups with regard to PRO (Table 5). Data at
discharge were not significantly different between groups
(Table 6).
From the time tDCs was discontinued until discharge, the
number of patients treated with opioids was not significantly
different between groups: 4 (14.8%) patients in tDCS group and 7
(25%) in sham group (p = 0.544). Additionally, there was no
significant difference in the amount of morphine used in tDCS
vs. sham group patients (20.00 (4.25–54.50) mg vs. 8.00 (3.00–
30.90) mg, (p = 0.788). The number of patients treated with
nonsteroidal anti-inflammatory drugs was 6 (22.2%) in tDCS
group vs. 3 (10.7%) in sham group (p = 0.295).
No patient contacted us after discharge due to pain problems.
The phone interview conducted 1 year after surgery revealed that 9
of 21 (43%) patients in the tDCS group and 11 of 22 (50%) patients
in the sham group had chronic pain (p = 0.87). Timing of chronic
pain appearancewas not significantly different between groups (p=
0.409): pain was persistent from the discharge in 4 (14.8%) tDCS
patients and in 6 (27.3%) sham patients. Pharmacologic chronic
pain treatmentwasneededby6 (28.6%)patients in tDCSgroupvs. 8
(36.4%) patients in the shamgroup (p= 0.444), but only one patient
in the tDCS group required opioid therapy. Pain influence on daily
activities 1 year after surgery was reported by two patients in the
sham group (p = 0.299).
DISCUSSION
Our results suggest that three to five anodal tDCS sessions on
consecutive post-operative days over the left primary motor
cortex (Brodmann areas 4) as an adjunct to IV morphine PCA
significantly reduce cumulative morphine use, pain with cough
and interference of pain on cough in patients with acute pain
after thoracotomy.
The use of opioid consumption given by IV PCA as the
primary outcome in our study is based on the principle that all
patients should have access to good quality postoperative
analgesia. Several published studies (Borckardt et al., 2008;
Borckardt et al., 2013; Glaser et al., 2016; Khedr et al., 2017b)
have used tDCS as component of a multimodal analgesia
regimen that also included IV opioids for pain after several
different types of surgical procedures and have demonstrated
significant reduction of cumulative PCA opioid use, comparable
to our findings. A study published by Ribeiro et al. (2017)
reported the best result with 73.25% reduction of opioid






Surgery duration (min) 144.44 (33.16) 152.36 (33.27) 0.381a






Pre tDCS morphine loading
(mg)
16.28 (6.75) 17.43 (6.96) 0.537a
Surgery type
Lobectomy 23 19 0.383b
Pneumonectomy 4 9
Data analysis did not show any significant differences between the active vs. sham group.
Pre-tDCS morphine loading is the amount of morphine needed to achieve visual analog
scale (VAS) pain ≤30 at rest.
tDCS, transcranial direct current stimulation.
aIndependent t-test.
bChi-square test.
FIGURE 3 | Cumulative morphine dose administered during the first 120 h
after surgery. Data are presented as median [(interquartile range (IQR)]. (○)
represents outliers. Day 0 covers the period after the first transcranial direct
current stimulation (tDCS) immediately after surgery until the second tDCS
session; postoperative day 1 covers the period after the second tDCS
session on the first postoperative day; postoperative day 2 covers the period
after the third tDCS session; postoperative day 3 covers the period after the
fourth tDCS session; postoperative day 4 covers the period after the fifth
tDCS session. After the fifth interventional session, cumulative morphine dose
was significantly lower (p = 0.043) in the tDCS group. *p < 0.05.
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Male (n = 16) Female (n = 5) Male (n = 23)
Day 0 30 (8–44) 43 (31.75–54.5) 20 (16–47) 44 (35–68) 0.913 0.454 0.050* 0.039*
Day 1 50 (28–68) 86.5 (64.25–105.8) 46 (36.5–73.5) 80 (68–121.5) 0.827 0.601 0.007* 0.019*
Day 2 68 (29–79.3) 98.5 (66.25–138.88) 57 (45–79) 103 (88.45–150) 1.000 0.373 0.008* 0.004*
Day 3 68 (29–79.3) 106.5 (66.5–168.90) 71.3 (48–87.55) 115 (89–174) 0.661 0.404 0.008* 0.007*
Day 4 68 (29–79.3) 106.5 (66.5–186.80) 76.3 (53–95.55) 123.8 (89–174.95) 0.441 0.373 0.008* 0.016*
Data are presented as median [interquartile range (IQR)]. Day 0 covers the period after the first transcranial direct current stimulation (tDCS) immediately after surgery until the second tDCS
session; postoperative day 1 covers the period after the second tDCS session on the first postoperative day; postoperative day 2 covers the period after the third tDCS session;
postoperative day 3 covers the period after the fourth tDCS session; postoperative day 4 covers the period after the fifth tDCS session. Compared to men, cumulative morphine dose was
significantly lower in women in both the tDCS and in the sham group at all times.
*p < 0.05 (Mann–Whitney U test).
FIGURE 4 | Maximum visual analog scale (VAS) pain scores during rest (A), movement (B), and cough (C). Data are presented as median (IQR). (○) represents
outliers. Day 0 covers the period after the first transcranial direct current stimulation (tDCS) immediately after the surgery until second tDCS session; postoperative
day 1 covers the period after the second tDCS session on the first postoperative day; postoperative day 2 covers the period after the third tDCS session;
postoperative day 3 covers the period after the fourth tDCS session; postoperative day 4 covers the period after the fifth tDCS session. (C) Significantly lower (p =
0.018) maximum VAS pain score with cough was recorded after the fifth interventional session in tDCS group. * p < 0.05.
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analgesic use with preoperative application of two tDCS sessions
in patients undergoing hallux valgus surgery. However, the
Ribeiro study included data collected from patient diaries after
hospital discharge (Ribeiro et al., 2017), whereas opioid
consumption data in our study as well as in several other
hospital-based studies were collected in an objective manner,
from PCA pumps in a hospital environment. The opioid sparing
effect of M1-tDCS can be explained by acute motor cortex
neuromodulation and direct increase of regional endogenous
opioid release (Dossantos et al., 2012; Dossantos et al., 2014).
Dossantos et al. (2012) have shown that acute tDCS reduces
morphine (µ) opioid receptor (MOR) availability in pain-related
regions during single-session tDCS in postherpetic neuralgia.
The decreased binding of exogenous ligand during PET scan was
explained as MOR occupancy by endogenous opioids (Maarrawi
et al., 2007). However, Khedr et al. (2017b) suggested that the
opioid sparing effect of tDCS could be the result of tDCS boosting
the opioid effect or of reduced endogenous perception of pain.
The variable opioid-sparing effect in different tDCS studies
can be explained by high heterogeneity of study protocols (twice
daily vs. once daily), use of different cortical targets (motor cortex
vs. prefrontal cortex), different non-opioid analgesics, including
metamizole, paracetamol or ketorolac, different types of surgical
procedures, and localization in the human body. Some studies
used a combination of spinally delivered local anesthetic and
opioid for intraoperative analgesia and postoperative systematic
opioid (Khedr et al., 2017b; Ribeiro et al., 2017), while other
studies, including our study, used perineural local anesthetic
administration as adjunct to systemic opioid analgesia
(Borckardt et al., 2013). Perineural local anesthetics (femoral
nerve block, intercostals block) and systemic non-opioid
analgesics (nonsteroidal and steroidal anti-inflammatory drugs)
act primarily by peripheral mechanisms (Eisenach and Brennan,
2018), while spinally administered drugs and systemic opioids
act primarily in the central nervous system (Eisenach and
Brennan, 2018). Based on the works of Nitsche et al. (2003a)
and Alonzo et al. (2012), different medications can influence
tDCS efficacy, thereby influencing the results of clinical trials.
The influence of multiple perioperative analgesics and regional
analgesia techniques on tDCS efficacy needs to be explored in
further studies.
In our study we tried to overcome some of these issues by
excluding patients with chronic pain and preoperative opioid
use. In an attempt to use fewer medications, propofol, and
remifentanil were used for anesthesia, combined with a single
intercostal block and a single dose of paracetamol
intraoperatively, followed by postoperative analgesia using
morphine IV-PCA. During the intraoperative period there was
no difference in the amount of remifentanil infused for
intraoperative analgesia and in the amount of morphine used
to provide analgesia at rest (VAS < 30 mm), before the first
TABLE 4 | Anxiety level, mood and Beck depression scores preoperatively and









Preoperatively 20.00 (00.00–41.00) 19.50 (00.00–30.00) 0.793c
Discharge 0.00 (00.00–00.00) 0.00 (00.00–00.00) 0.634c
Mood VAS (mm)
Preoperatively 85.00 (60.00–95.00) 89.50 (82.25–97.25) 0.294c
Discharge 100.00 (95.00–100.00) 100.00 (90.00–100.00) 0.507c
Beck depression
scale (points)
Preoperatively 4.00 (1.00–6.00) 2.00 (0.00–5.00) 0.396c
Discharge 5.00 (1.00–7.00) 3.00 (0.50–7.00) 0.465c
Data are presented as median (IQR). Data analysis did not show any significant differences
between the active vs. sham group.
cMann–Whitney test.







Day 1 40.00 (30.00–70.00) 55.00 (40.00–70.00) 0.339c
Day 5 50.00 (27.50–70.00) 50.00 (40.00–80.00) 0.473c
Percentage of time
in severe pain (%)
Day 1 5.00 (5.00–10.00) 10.00 (5.00–10.00) 0.220c
Day 5 20.00 (10.00–30.00) 30.00 (10.00–45.00) 0.342c
Pain interference
with movement
Day 1 10.00 (0.00–30.00) 7.50 (0.00–17.50) 0.409c
Day 5 20.00 (0.00–50.00) 40.00 (0.00–60.00) 0.394c
Pain interference
with cough
Day 1 0.00 (0.00–5.00) 5.00 (0.00–10.00) 0.160c
Day 5 10.00 (0.00–30.00) 50.00 (0.00–70.00) 0.013c
Pain interference
with sleep
Day 1 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.806c
Day 5 10.00 (00.00–30.00) 20.00 (0.00–60.00) 0.334c
Satisfaction with
pain management










Data are presented as median (IQR). Pain interference with cough was significantly higher
in the sham group on day 5 (p < 0.013).
cMann–Whitney test.
TABLE 6 | Postoperative data; VAS-pain (P) on discharge, hospital length of








7.00 (6.50–8.00) 8.00 (7.00–11.25) 0.126c
Drain length of
presence (days)
3.45 (2.00–4.50) 2.50 (1.00–4.00) 0.166c
VAS-P rest (mm) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.372c
VAS-P movement
(mm)
10.00 (0.00–25.00) 0.00 (0.00–30.00) 0.653c
VAS-P cough (mm) 20.00 (0.00–35.00) 8.00 (0.00–30.00) 0.349c
Data are presented as median (IQR). Data analysis did not show any significant differences
between the active vs. sham group.
cMann–Whitney test.
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intervention session in the immediate postoperative period. In
the postoperative period, paracetamol was given only when a
patient requested additional analgesia, and none of the patients
requested it. However, despite well-defined exclusion criteria,
our patients were still using different medications for treatment
of chronic comorbidities.
Propofol was chosen as primary anesthetic because data
suggest it confers neuroprotective effect against intercostal
nerve injury after thoracotomy (Song et al., 2012) and may
also have a role in preventing remifentanil-induced
hyperalgesia (Song et al., 2012). Remifentanil was chosen for
intraoperative use in order to minimize the impact of
intraoperative opioid administration on postoperative analgesia
and on the need for postoperative opioids. Morphine
administration started at the time of the “air leak test” (testing
of the bronchial stump and lobe for air leak), usually 40 min
before closing the chest (Munoz et al., 2002).
Cumulative opioid use in our study showed divergent
trajectories between the two groups, with the divergence getting
wider after the second tDCS session, a finding similar to the results
reported byKhedr et al. (2017b). Other studies have shown that the
effect of tDCS becomes obvious 12 h after the first tDCS session or
after two tDCS sessions (Glaser et al., 2016; Borckardt et al., 2017).
Borckardt et al. (2017) have suggested that tDCS should be used
immediately after surgery in order tomaximize its effect, but in our
study and in several other studies the first tDCS session started 30
min to 3 h after wound closure. In contrast to earlier studies which
did not precisely evaluate pre tDCS pain intensity, the first tDCS
session was started in our study only after patients received
postoperative analgesics and VAS pain at rest was ≤30 mm, in
order to have comfortable patients with similar pain intensity at the
time of tDCS. The number of analgesia requests was recorded;
however, PCA settings were adjusted in response to patients’ needs
by increasing the bolus dose ofmorphine from1 to 2mg, and this is
why there was no difference in the number of analgesia requests.
Therefore, the amount of morphine used (not the number of
analgesia requests) better reflects the quality of analgesia in this
patient population.
While the Ribeiro et al. study only included female patients, our
study included bothmen andwomen.Whenanalyzingdata inmale
patients only and in female patients only, we did not find any
significant difference between tDCS vs. sham groups with regard to
cumulative morphine use and maximum pain scores. However,
when comparing male vs. female patients, data analysis showed
significantly higher cumulativemorphine use inmale patients at all
time points in the postoperative period. Published studies have not
shown sex to be a consistent predictor of analgesic efficacy of
morphine: some studies found reduced morphine efficacy
(Cepeda and Carr, 2003; Miller and Ernst, 2004) or increased
morphine efficacy (Niesters et al., 2010) in female patients, while
other studies showednodifference (Fillingim et al., 2005), and there
is a hypothesis that different genotypes, especially polymorphismof
OPRM1generesponsible forMORsynthesis (Janicki et al., 2006; Sia
et al., 2008) might play an important role.
In our study, VAS pain scores at rest, with movement and
with cough were not different between the two groups, but
cumulative opioid use was significantly lower in the tDCS
group. This finding is in agreement with the findings reported
by Khedr et al. (2017b) and suggests that tDCS has a significant
analgesic and opioid-sparing effect. However, because the main
outcome of our study was cumulative opioid use, the study was
not designed and did not have adequate power to assess
differences in postoperative VAS scores between patient
groups. Therefore, we decided to analyze the maximum value
of pain during cough, i.e., “the worst possible pain” which, as
suggested by Jensen et al. (2015) is more important than “average
pain” for valid assessment of the treatment effect. In the tDCS
treated group, maximum VAS pain during cough was
significantly lower after the fifth tDCS session on postoperative
day 5. This finding can be explained by a cumulative effect of
repeated tDCS, as reported in tDCS studies on healthy volunteers
and patients with chronic pain (Lima and Fregni, 2008; Alonzo
et al., 2012).
Our decision to include in data analysis only patients who had
three or more tDCS sessions was based on the concept of
cumulative tDCS effect. Driven by the positive benefits of
repeated rTMS sessions for the treatment of depression, many
trials have applied the same concept using tDCS. Clinical trials
have applied repeated tDCS sessions with the assumption that
repeated stimulation will result in cumulative and sustained
changes in cerebral function (Mori et al., 2010). Recent
evidence suggests that the excitatory effects derived from tDCS
might be cumulative both at the cortical (Alonzo et al., 2012) and
at the behavioral level in healthy people as well as in different
patient populations (Boggio et al., 2008a; Alonzo et al., 2012).
Furthermore, tDCS alters cortical excitability more effectively
when given daily rather than every other day over a 5-day period
(Alonzo et al., 2012). Most studies showing an effect of tDCS on
opioid consumption have design similar to our study, using four
tDCS sessions, either as two sessions per day for 2 days or as one
session per day for four consecutive days (Borckardt et al., 2013;
Glaser et al., 2016; Khedr et al., 2017b), whereas two studies used
only one tDCS session with different results (Borckardt et al.,
2011; Dubois et al., 2013). Based on this knowledge, data analysis
in our study was performed “per protocol”.
We believe that the 34.83% reduction of maximum VAS pain
during cough observed after the fifth tDCS session is clinically
significant, based on mean value which stratifies tDCS group
patients with mild pain compared to moderate pain in sham
group (Jensen et al., 2003; Younger et al., 2009).
Some published studies have not shown a benefit from tDCS
withregard topain scores (Khedr etal., 2017b).Thebest resultshave
been reported with preoperative tDCS application (Ribeiro et al.,
2017), but in that study datawere recorded and collected bypatients
at home. The model of post-thoracotomy pain used in our study is
challengingdue to the complexorigin ofpain, includingnociceptive
(skin incision), somatic (muscles, ribs) caused by retraction and
deeper tissue trauma, resection of ribs and dislocation of
costovertebral joints, visceral (pleura) caused by chest tube
irritation, and nerve involvement due to intercostal nerve injury
and inflammation (Ochroch and Gottschalk, 2005). Intercostal
nerves, and the vagus and phrenic nerves are all responsible for
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nociceptive input after thoracotomy. Intercostal nerve injury due to
incision, retraction, or suture can have significant impact on post-
thoracotomy pain (Benedetti et al., 1998), whereas phrenic nerve
activity can cause shoulder pain (Scawn et al., 2001). Furtherwork is
needed to evaluate whether other surgical procedures are
“responding” to the analgesic effect of tDCS.
Postoperative pain is complex andnot a single entity.Use of tDCS
in patients with chronic pain state (fibromyalgia) can result in mood
improvement (Khedr et al., 2017a), whereas studies investigating
acute postoperative pain, including our study, did not find a
difference in mood and depression scores between patients treated
with tDCS vs. sham (Borckardt et al., 2013; Khedr et al., 2017a). The
different effect of tDCS on mood and depression scores in patients
with acute vs. chronic pain can be explained by the different pain
model, stimulation electrode location, lower number of tDCS
sessions, and, perhaps more important, other psychological factors,
including catastrophization, which are not evaluated in clinical acute
pain studies (Borckardt et al., 2013; Khedr et al., 2017a; Lefaucheur
et al., 2017).
In our study, tDCS showed short-term benefit as evidenced by
significant reduction of morphine use. However, patient follow-
up during hospital stay and the follow-up phone interview 1 year
later did not show a difference between groups with regard to
analgesic medication use and incidence of chronic pain, which
were not the primary aims of the study. This short-term
beneficial effect of tDCS could still be clinically relevant as part
of multimodal post-thoracotomy pain treatment in cases where
regional techniques have failed or are contraindicated. Because
the severity of acute post-thoracotomy pain has been associated
with chronic pain after surgery (Bayman et al., 2017; Niraj et al.,
2017), different analgesic techniques, especially non-
pharmacological opioid-sparing techniques with minimal side
effects should be explored for their utility in clinical practice.
Strengths of our study include the use of a nonpharmacological
and safe technique as part of multimodal analgesia regimen for a
very painful surgery (thoracotomy), prospective study design, small
but adequate sample size, sound blinding and randomization
procedures, and a clinically meaningful primary outcome. The
finding of reduced “worst possible pain” during cough is clinically
important for patients in the postoperative period and is especially
useful after video assisted thoracoscopic surgery (VATS) and in
cases where epidural analgesia is contraindicated.
Limitations of our study include the small (but adequate,
based on sample size calculation) number of patients, and the
absence of preoperative qualitative sensory testing which could
provide additional insight into the character of patient distress.
The fifth intervention session was performed in 11 patients in the
tDCS group and 16 patients in the sham group, therefore we
calculated Cohen’s criteria of d 0.42, which shows that sample
size has low impact on results.
Although previous publications have used two tDCS sessions
per day (Borckardt et al., 2013; Glaser et al., 2016; Borckardt et al.,
2017), we chose to use single tDCS session repeated daily based on
previously published data (Borckardt et al., 2011; Khedr et al.,
2017a). From our point of view, daily application of tDCS
stimulation seems more feasible in the real world of a busy hospital.
The short-term (5 days) follow-up period is a significant
limitation of this study, but was based on average hospital stay
after thoracotomy in our Institution. This was a “proof of
concept” study, as there are no published data about the effects
of tDCS as part of multimodal management of acute post-
thoracotomy pain. However, after patients leave the hospital,
our experience showed that it is difficult to achieve high patient
response rates to phone interviews and patients are generally not
willing to participate in repeated follow-up audits. Therefore, in
order to respect the wishes of our patients to only be contacted
once after surgery, we determined that a 1-year follow-up period
was the most suitable.
Recently, tDCShas been increasingly studied as an effective pain
treatment technique (Woods et al., 2016). This type of non-invasive
modulation has been studied previously in multiple target brain
areas including the primary motor cortex, dorsolateral prefrontal
cortex, and less frequently cerebellum(O'connell et al., 2014). Inour
study we decided to stimulate the primary motor cortex, since this
pattern of stimulation has proven to be successful in a number of
previous studies. This choice of target region is based on presumed
modulation of the lateral thalamus hyperactivity by input from
cortico-thalamic projections originating from the primary motor
cortex, which is considered to be related to sensory-discriminative
information processing (Boggio et al., 2008b). Considering
limitations related to tDCS methodological issues, it should be
noted that in this study we chose a pattern of stimulation based on
the experience of most previous studies, applying standard
electrode positioning (C3-Fp2), which, may have contributed to
reduced stimulation efficacy. On the contrary, we opted for a
relatively strong and focal stimulation, especially considering that
these patients receive analgesics as primary therapy after surgery,
and tDCS can be tolerated without significant side effects. It is also
worth noting that with tDCS montage as applied, the return
electrode positioned over the right prefrontal cortex (Fp2) could
also contribute to pain alleviation. Moreover, studies on the
processing of painful information in the brain, in addition to
activation of the thalamus, insular cortex, anterior cingulate
cortex, and primary and secondary areas of the somatosensory
cortex, also indicate activation of the prefrontal cortex (Ong et al.,
2019). Therefore, in future research, the protocol could be
systematic shaping, with possible consideration of another anode
position (C1 position would probably be the most suitable area for
the thoracic area, instead of C3 as we used), and the choice of
hemisphere stimulation could be adjusted so that tDCS can always
be applied on the contralateral side, depending on the side of the
chest where thoracotomy was performed.
Nonpharmacological techniques can be viewed as measures
aiming to reduce postoperative opioid use. Resources among
hospitals vary widely and not all analgesia modalities are
available in every hospital; therefore, exploration of the
appropriate use of certain analgesic techniques can widen the
panel of analgesia techniques available and result in improved
hospital analgesic protocols. We suggest that future studies could
define proper timing for a preoperative tDCS session because
there are data suggesting that preoperative tDCS can also be
beneficial (Ribeiro et al., 2017).
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In conclusion, our study suggests that postoperative daily
tDCS confers significant benefits with regard to postoperative
analgesia after thoracotomy, and this benefit is probably
applicable not only for open thoracic surgery, but also for
postoperative pain management after VATS, when planned
thoracoscopic procedures require conversion to open surgery
and after emergency thoracotomy. Because the conclusion about
lack of long-term tDCS efficacy on pain in our study is based
only on one telephone survey conducted 1 year after surgery, we
suggest that future studies could better explore possible tDCS
effects on chronic postoperative pain presence by also collecting
data about pain 3 and 6 months after surgery.
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